Amryt's Wings Clipped By Delay For Butterfly Skin Drug Decision
FDA Puts Back Filsuvez PDUFA Date To End Of February
The Irish firm needs to give regulators in the US more information on its epidermolysis bullosa therapy but is confident of address those requests from its "existing data within the time periods required," according to CEO Joe Wiley.
